Paul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) Stock

Key Points

• Paul Mahon, Executive VP of United Therapeutics, sold 8,300 shares on March 19 at an average price of $529.95 for a total of $4.398M, cutting his holding by 15.52% to 45,172 shares, per an SEC filing.
• United Therapeutics reported quarterly EPS of $7.70 (beating estimates by $0.92) while revenue of $790.2M slightly missed forecasts; the company shows a high net margin (41.94%) and analysts hold a Moderate Buy consensus with a $548.09 target price.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $529.95, for a total transaction of $4,398,585.00. Following the completion of the transaction, the executive vice president owned 45,172 shares of the company's stock, valued at $23,938,901.40. This represents a 15.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

United Therapeutics Stock Down 0.6%

United Therapeutics stock traded down $3.35 during trading hours on Thursday, hitting $527.00. 504,858 shares of the company traded hands, compared to its average volume of 434,849. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $548.12. The firm has a market cap of $23.10 billion, a P/E ratio of 18.89, a P/E/G ratio of 1.94 and a beta of 0.84. The firm's 50-day simple moving average is $488.85 and its two-hundred day simple moving average is $465.99.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping analysts' consensus estimates of $6.78 by $0.92. The company had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business's revenue for the quarter was up 7.4% compared to the same quarter last year. During the same period in the prior year, the business posted $6.19 EPS. On average, equities research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Institutional Investors Weigh In On United Therapeutics

Several hedge funds have recently modified their holdings of the stock. Torren Management LLC acquired a new position in United Therapeutics in the 4th quarter valued at approximately $26,000. Activest Wealth Management boosted its stake in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock valued at $29,000 after buying an additional 56 shares during the period. WealthCollab LLC grew its holdings in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. increased its stake in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 46 shares during the last quarter. Finally, Entrust Financial LLC acquired a new position in shares of United Therapeutics in the fourth quarter worth $31,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on UTHR shares. Bank of America reaffirmed a "neutral" rating on shares of United Therapeutics in a research note on Wednesday, February 25th. Wells Fargo & Company upped their price objective on United Therapeutics from $423.00 to $466.00 and gave the company an "equal weight" rating in a report on Thursday, February 26th. Royal Bank Of Canada raised their target price on United Therapeutics from $587.00 to $643.00 and gave the company an "outperform" rating in a research note on Thursday, February 26th. TD Cowen lifted their target price on United Therapeutics from $525.00 to $575.00 and gave the stock a "buy" rating in a report on Wednesday, February 25th. Finally, Oppenheimer upped their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a report on Thursday, February 26th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, United Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $548.09.

United Therapeutics Company Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.